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The management of pericardial diseases is largely empir-ical because of the relative lack of randomized trials. The
first published guidelines1,2 are a first attempt to organize
current knowledge. At present, no specific guidelines have
been issued by the American Heart Association and Ameri-
can College of Cardiology. After a literature review including
a Medline search with the MeSH terms “pericarditis” and
“pericardium,” we identified the following controversial is-
sues related mainly to the management of pericarditis and
pericardial effusion: (1) etiological search and hospitaliza-
tion; (2) role of pericardiocentesis, pericardial biopsy, and
pericardioscopy; (3) myopericarditis; (4) use of corticoste-
roids, nonsteroidal antiinflammatory drugs (NSAIDs), and
colchicine; (5) management of refractory cases and long-term
outcome; (6) role of pericardiectomy, pericardial window,
and other interventional techniques; and (7) management of
chronic idiopathic pericardial effusion.
At the end of each issue, key points are summarized.
Management of most cases is done by general practitioners or
different healthcare specialists and does not require specific
expertise; nevertheless, incessant and recurrent cases and
specific forms (eg, tuberculous pericarditis, neoplastic peri-
cardial disease, autoimmune conditions) require cooperation
among specialties (eg, cardiology, infectious diseases, rheu-
matology, oncology). Specific interventional techniques (eg,
pericardioscopy) and pericardiectomy should be performed in
referral centers.
Etiological Search and Hospitalization
Pericarditis
Although the clinical diagnosis of pericarditis is relatively
simple (Tables 1 and 2),1–13 establishing the cause may be
more difficult. A major controversy in “pericardiology” is the
role of an extensive etiologic search and hospital admission
for all patients with pericarditis or pericardial effusion.1–8 The
causes of pericarditis are varied (Table 3),9 and the clinician
should identify causes that require targeted therapies. The
epidemiological background is essential to develop a rational
cost-effective management program3,4,15,16; the approach may
be different for research, when we attempt to reduce the
number of “idiopathic” cases. In developed countries, idio-
pathic or viral pericarditis is the commonest final diagnosis in
the immunocompetent patient,5–7 and a more precise diagno-
sis is often irrelevant for the management of most
patients.10–13
Basic diagnostic evaluation should include auscultation;
ECG; transthoracic echocardiography; routine blood tests,
including markers of inflammation (ie, C-reactive protein
[CRP] and/or erythrocyte sedimentation rate [ESR]) and
myocardial lesion (creatine-kinase, troponins); and chest
x-ray in all cases of suspected pericarditis.2 Additional tests
should be related to suspected origin.
The major specific causes to be ruled out are tuberculous
pericarditis, neoplastic pericarditis, and pericarditis associ-
ated with a systemic disease (generally an autoimmune
disease). Each of these specific causes has a frequency of
5% of all unselected cases of pericarditis from developed
countries (Table 4).5–7 Emerging additional causes include
iatrogenic origins (percutaneous coronary interventions,
pacemaker insertion, catheter ablation).14 These are contem-
porary examples of postcardiac injury syndromes in which
the etiology is determined by a combination of direct peri-
cardial trauma, pericardial bleeding, and individual predispo-
sition. Tuberculous pericarditis may be found in North
America and Western Europe, especially among immigrants
from areas with a high prevalence of tuberculosis and
HIV-infected patients. The etiologic spectrum is different in
developing countries, with a high prevalence of tuberculosis
(eg, 70% to 80% of pericarditis in sub-Saharan Africa, and
90% when associated with HIV infection).15,16
Certain clinical features indicating high risk are proposed
for triage of pericarditis and the need for a full etiologic
search and admission (Table 5).4,8,17,18 Some of these features
were validated by multivariable analysis7; fever 38°C
(hazard ratio [HR], 3.56), subacute course (symptoms devel-
oping over several days or weeks; HR, 3.97), large pericardial
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effusion (diastolic echo-free space 20 mm in width) or
cardiac tamponade (HR, 2.15), and failure of aspirin or
NSAIDs (HR, 2.50) were independent predictors of a specific
cause (nonviral or nonidiopathic) in a prospective study of
450 consecutive cases of acute pericarditis. Large effusion
and tamponade (HR, 2.51) and aspirin or NSAID failure (HR,
5.50) identified increased risk of complications during
follow-up.7 Women were at increased risk of specific causes
and complications because of a higher prevalence of systemic
autoimmune diseases. For patients with poor prognostic
predictors (Table 5), hospitalization and a full etiologic
search are warranted (Figure 1).4,8,17,18 On the contrary, when
these negative predictors are absent, patients are at low risk of
specific causes and complications, and outpatient manage-
ment has been proposed. In a prospective study of 300
consecutive patients with acute pericarditis, 254 patients
(85%) were at low risk and not admitted to hospital but were
Table 1. Diagnostic Criteria for Pericarditis
Criteria
Typical chest pain
Pericardial friction rub
Suggestive ECG changes (typically widespread ST-segment elevation, PR
depression)
New or worsening pericardial effusion*
*The inclusion of pericardial effusion, not universally accepted,1,5 is justified
considering that this feature, although not necessary, is a confirmatory finding
when present. Elevation of CRP is a confirmatory finding and is required for the
diagnosis of acute and recurrent pericarditis by some authors.4,11–13
Table 2. Recommended Basic Routine Diagnostic Evaluation
for Pericarditis
Diagnostic Tool* Data to Evaluate for the Diagnosis
Mandatory (class I)
Cardiac auscultation Pericardial rub
ECG PR ST-T changes
Transthoracic
echocardiography
Pericardial effusion
Blood tests† Markers of inflammation (ESR, CRP),
blood cell count, creatinine, markers of
myocardial lesion (troponin, CK-MB)
Chest x-ray Pleural effusion, cardiac size,
concomitant pleuropulmonary disease
According to presentation
features
Etiology search on pericardial fluid
Pericardiocentesis for cardiac
tamponade (class I)
Pericardiocentesis for
persistent significant
pericardial effusion without
clear diagnosis (class IIa)
Pericardiocentesis for
persistent mild pericardial
effusion (class IIb)
Optional if persistent disease
and initial diagnostic test are
inconclusive (class IIa) and with
suspicion of nonidiopathic
cause
Search for specific disease (eg,
tuberculosis, neoplasia)
CT
CMR
Pericardioscopy and
pericardial biopsy
Targeted pericardial biopsy
CK-MB indicates creatine kinase-MB; CMR, cardiac magnetic resonance. At
least 2 of the 4 criteria should be present.
*Classes of recommendations are based on 2004 European Society of
Cardiology guidelines.2
†Additional blood testing should be performed if a specific cause is suspected;
routine viral serology and viral etiology search are not routinely recommended and
have no impact on subsequent therapy in the clinical setting.
Table 3. Causes of Pericarditis: A Simple Basic Classification
in Infectious and Noninfectious Forms
Infectious pericarditis (2/3 of cases)
Viral (most common: echovirus and coxsackievirus (usual), influenza, EBV,
CMV, adenovirus, varicella, rubella, mumps, HBV, HCV, HIV, parvovirus
B19, and human herpes virus 6 (increasing reports)
Bacterial (most common: tuberculous 4%–5%, Coxiella burnetii ; other
bacterial rare may include pneumococcosis, meningococcosis,
gonococcosis, haemophilus, staphylococci, chlamydia, mycoplasma,
legionella, leptospira, listeria)
Fungal (rare; histoplasma more likely in immunocompetent patients;
aspergillosis, blastomycosis, candida more likely in immunosuppressed
host)
Parasitic (very rare; echinococcus, toxoplasma)
Noninfectious pericarditis (1/3 of cases)
Autoimmune pericarditis (10%)
Pericardial injury syndromes (post–myocardial infarction syndrome,
postpericardiotomy syndrome, posttraumatic pericarditis including
iatrogenic pericarditis, eg, post–percutaneous coronary interventions,
post–pacemaker insertion, postablation)
Pericarditis in systemic autoimmune and autoinflammatory diseases
(more common in systemic lupus erythematosus, Sjögren syndrome,
rheumatoid arthritis, systemic sclerosis, systemic vasculitides, Behçet
syndrome, sarcoidosis, familial Mediterranean fever)
Autoreactive pericarditis
Neoplastic pericarditis (5% to 7%)
Primary tumors (rare; above all pericardial mesothelioma)
Secondary metastatic tumors (common; above all lung and breast
cancer, lymphoma)
Metabolic pericarditis (common; uremia, myxedema; others rare)
Traumatic pericarditis (rare)
Direct injury (penetrating thoracic injury, esophageal perforation,
iatrogenic)
Indirect injury (nonpenetrating thoracic injury, radiation injury)
Drug-related pericarditis (rare); procainamide, hydralazine, isoniazid, and
phenytoin (lupus-like syndrome), penicillins (hypersensitivity pericarditis
with eosinophilia), doxorubicin, and daunorubicin (often associated with a
cardiomyopathy; may cause a pericardiopathy)
EBV indicates Epstein-Barr virus; CMV, cytomegalovirus; HBV, hepatitis B
virus; and HCV, hepatitis C virus. Percentages refer to unselected cases. The
diagnosis of autoreactive pericarditis is established in the European guidelines
using the following criteria: (1) increased number of lymphocytes and
mononuclear cells 5000/mm3 (autoreactive lymphocytic) or the presence of
antibodies against heart muscle tissue (antisarcolemmal) in the pericardial fluid
(autoreactive antibody mediated), (2) signs of myocarditis on epicardial/endo-
myocardial biopsies by 14 cells/mm2, and (3) exclusion of infections,
neoplasia, systemic, and metabolic disorders.2
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treated empirically with aspirin 800 mg every 6 or 8 hours for
7 to 10 days without an etiologic search. The protocol was
safe (no cases of cardiac tamponade) and cost-effective; 230
of 254 low-risk cases (90.6%) had a final diagnosis of viral or
idiopathic pericarditis after a mean follow-up of 38 months.10
The same approach is also useful for patients with recur-
rences that may generally be treated as outpatient unless poor
prognostic predictors are present or a specific cause can be
ruled out. With a clear diagnosis of idiopathic origin, it is also
unnecessary to repeat a new etiologic search at each recur-
rence unless new clinical features become evident. The
commonest causes of recurrences are idiopathic, viral, auto-
immune (usually related to a connective tissue disease or a
pericardial injury syndrome), inadequate medical treatment of
either the index attack or the recurrence, and less commonly,
a neoplastic origin.11,19 Recurrent pericarditis often has the
features of a systemic inflammatory disease, particularly at
the onset. Pleuropulmonary involvement occurs in one third
of adults13 and in two thirds of pediatric patients,20 and liver
involvement is seen in 8%,13 so idiopathic recurrent pericar-
ditis shares several features with autoinflammatory diseases21
such as familial Mediterranean fever.
Pericardial Effusion
Clinical series with pericardial effusion have reported a lower
rate of idiopathic causes compared with acute pericarditis
(Table 6). Moderate to large pericardial effusions had specific
diagnoses (nonidiopathic origins) in up to 90%, and neo-
plasms, tuberculosis, and myxedema should be consid-
ered.22–24 Although reported frequencies vary according to
geographic distribution, selection criteria (ie, definition of
effusion severity), and medical setting (ie, general versus
tertiary referral centers), the origin of pericardial effusion can
be suspected by the clinical presentation. A selective ap-
proach may consider the presence/absence of cardiac tam-
ponade; any inflammatory signs, including CRP and/or ESR
(ie, pericarditis); known medical conditions (up to 60% of
cases); and effusion size. Cardiac tamponade requires drain-
age and etiology search and, when the presentation is without
inflammatory signs, is associated with a higher risk of
neoplasia (likelihood ratio, 2.9).23 If inflammatory signs are
present, the clinical approach should be that of pericarditis.
Known medical conditions are reported in up to 60% of cases
with a moderate to large effusion.23 A large effusion without
cardiac tamponade, inflammatory signs, and a known medical
condition is usually associated with a chronic idiopathic
origin (likelihood ratio, 20).23 In this condition, a normal
chest computed tomography scan may be helpful in ruling out
neoplasms and tuberculosis. A practical approach is depicted
in Figure 2. A detailed discussion of laboratory tests and
integrated cardiovascular imaging for the etiology search for
pericarditis and pericardial effusion is beyond the scope of
this article (see the online-only Data Supplemental). Table 7
summarizes the relative contributions of diagnostic tools for
specific etiologic search.
Key points: (1) Basic diagnostic tests for all cases with
suspected pericarditis include ECG, transthoracic echocardi-
ography, markers of inflammation (CRP and/or ESR) and
myocardial lesion (eg, troponin), and chest x-ray; (2) addi-
tional tests, hospitalization, and etiology search should be
restricted to high-risk patients; (3) major high-risk features
(predictive of possible nonviral, nonidiopathic origins, and
complications during follow-up) include fever 38°C, sub-
acute course, large pericardial effusion or cardiac tamponade,
and failure of aspirin or NSAIDs.
Role of Pericardiocentesis and
Pericardial Biopsy
The first studies of pericarditis5,6 reported a low diagnostic
yield for diagnostic pericardiocentesis and pericardial biopsy.
Other authors have advocated a more extensive use of the
techniques for diagnostic purposes.2
When a significant pericardial effusion is present, diagnos-
tic pericardiocentesis is mandatory if a specific origin is
suspected and diagnosis cannot be reached by other means.2
Pericardiocentesis may also be considered for large or symp-
tomatic effusions refractory to medical treatment. Pericardio-
centesis may be guided by fluoroscopy or echocardiography.
If hemorrhagic fluid is aspirated, it is practical to remember
that fibrinolytic activity in the pericardium prevents blood
clotting in subacute and chronic effusion. However, acute
hemorrhage into the pericardium overwhelms fibrinolysis,
Table 5. Clinical Poor Prognostic Predictors* for Pericarditis
Major
Fever 38°C
Subacute onset
Large pericardial effusion
Cardiac tamponade
Lack of response to aspirin or NSAIDs after at least 1 wk of therapy
Minor
Myopericarditis
Immunodepression
Trauma
Oral anticoagulant therapy
See text for details.
*Major predictors have been validated in multivariable analysis.7
Table 4. Final Etiologic Diagnosis in Major Published Series of
Acute Pericarditis (Unselected Patients)
Permanyer-
Miralda
et al5
(n231)
Zayas
et al6
(n100)
Imazio
et al7
(n453)
Reuter
et al16
(n233)*
Years 1977–1983 1991–1993 1996–2004 1995–2001
Setting Western
Europe
Western
Europe
Western
Europe
Africa
Idiopathic, n (%) 199 (86.0) 78 (78.0) 377 (83.2) 32 (13.7)
Specific cause,
n (%)
32 (14.0) 22 (22.0) 76 (16.8) 201 (86.3)
Neoplastic 13 (5.6) 7 (7.0) 23 (5.1) 22 (9.4)
Tuberculosis 9 (3.9) 4 (4.0) 17 (3.8) 161 (69.5)
Autoimmune 4 (1.7) 3 (3.0) 33 (7.3) 12 (5.2)
Purulent 2 (0.9) 1 (1.0) 3 (0.7) 5 (2.1)
*Based on pericardial effusions.
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and blood clotting can occur in fluid aspirated in such cases.
If the answer is not clear, contrast medium may be injected
under fluoroscopic observation and agitated saline under
echocardiographic observation to exclude cardiac puncture.25
Echocardiography-guided pericardiocentesis is safe and al-
lows different approaches to the effusion beyond the standard
“subxiphoid” route. The clinician may choose the best punc-
ture site closest to the large amount of pericardial fluid
identified by the echocardiogram also without a catheteriza-
tion laboratory.26 However, hemodynamic evaluation may
detect effusive-constrictive pericarditis.27 Elective pericardio-
centesis should be performed in a catheterization laboratory
when available. In this setting, the use of the echocardiogra-
phy-guided technique of pericardiocentesis will provide the
best integration of available diagnostic techniques to guide
pericardiocentesis. Echocardiography-guided pericardiocen-
tesis remains sufficient when a catheterization laboratory is
not available or in urgency/emergency settings.
In the first published studies, pericardial biopsy was
generally performed as part of a therapeutic procedure (sur-
gical drainage) in patients with cardiac tamponade relapsing
after pericardiocentesis (therapeutic biopsy). It was also used
as a diagnostic procedure in patients with illness lasting 3
weeks without definite diagnosis.5
Technical advances in instrumentation with the intro-
duction of pericardioscopy, in contemporary virology, and
in molecular biology improved the diagnostic value of
epicardial/pericardial biopsy.2,28,29 Targeted biopsy during
pericardioscopy was particularly useful for diagnosing
neoplastic pericardial disease.29 Yet pericardioscopy is not
generally available outside tertiary referral centers, but
advanced diagnostic methods seem warranted in cases
refractory to full conventional therapy, suspected tubercu-
lous, or purulent or neoplastic pericarditis when the
diagnosis cannot be reached by other means (Table 8). The
diagnostic yield of pericardial biopsy is higher in patients
with pericardial effusion with or without pericarditis than
in those with apparent acute pericarditis without effusion
and increases with large effusions.22–24,30 Polymerase chain
reaction represents a useful adjunct to conventional labo-
ratory studies of pericardial samples, allowing rapid iden-
tification of microorganisms not easily found otherwise.31
However, some authors underlined the need for careful
selection of patients because molecular methods led to an
absolute increase in specific useful diagnoses in 5% of
cases in an already selected population.32 Although poten-
tially useful, if indicated without clinical judgment, mo-
lecular diagnostic techniques could lead to irrelevant
findings such as viral infections for which specific drugs
are not available or necessary in most cases.32 Table 7
summarizes the relative value of different diagnostic tests.
Key points: (1) Pericardiocentesis is indicated for cardiac
tamponade, high suspicion of tuberculous, purulent, or neo-
plastic pericarditis, and large or symptomatic effusions re-
fractory to medical treatment; (2) pericardial biopsy may be
indicated for diagnosis in patients with persistent worsening
illness without a definite diagnosis despite medical therapy
and as part of a therapeutic procedure for relapsing cardiac
tamponade or moderate to large effusions with severe symp-
toms; and (3) pericardioscopy for targeted diagnostic imaging
and biopsy may be indicated in refractory, difficult cases at
experienced tertiary referral centers.
Figure 1. In developed countries, a probabi-
listic approach is advisable in the immuno-
competent patient. Etiologic search should
rule out commonest causes: tuberculous,
purulent, and neoplastic pericarditis and
pericarditis related to a systemic disease.
Triage of pericarditis according to the
Torino experience.
Table 6. Etiologic Diagnosis in Major Published Series With
Pericardial Effusions
Corey et al22
(n57)
Sagrista et al23
(n322)
Levy et al24
(n204)
Year 1993 2000 2003
Size of effusion, mm 10 10 NR
Tamponade, % NR 37 NR
Idiopathic, % 7 29 48
Neoplasia, % 23 13 15
Infection, % 27 2 16
Connective tissue diseases, % 12 5 9
Metabolic, % 12 6 11
Iatrogenic, % 0 16 0
Other, % 19 29 1
NR indicates not reported. Data include main clinical diagnoses.
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Myopericarditis
Cases of pericarditis may present with troponin eleva-
tion,33–35 an expression of concomitant myocardial involve-
ment. Concomitantly, widespread ST-segment elevation, usually
considered a hallmark of acute pericarditis,1,2,17,18 shows sub-
epicardial myocardial involvement rather than simple
“pericarditis” (Figure 3). Thus, mixed myocardial and
pericardial involvement is probably present in most cases
with pericarditis. Myocarditis and pericarditis share com-
mon etiologic agents, mainly viruses; thus, a spectrum of
myopericardial inflammatory syndromes, ranging from
pure pericarditis to forms with increasing myocardial
involvement such as myopericarditis (predominant pericar-
ditis), perimyocarditis (predominant myocarditis), and
pure myocarditis, can be encountered.36 –38 Myopericardi-
Figure 2. Management of pericardial effu-
sion (see text for details).
Table 7. Utility of Diagnostic Tests for the Etiologic Diagnosis
of Pericarditis According to Targeted Causes
Test General Tuberculous
Systemic
Disease Neoplastic Purulent
Auscultation  / / / /
ECG  / / / /
Echocardiography     
Markers of
inflammation
    
Markers of
myocardial lesion
 /  / /
Tumor markers   /  
Tuberculin skin
test
 / /  
QuantiFERON-TB   /  
ANA, ENA
(anti-SSA)
    
HIV testing     
Viral serology     
Blood culture     
Chest x-ray     
CT     
CMR     
Mammography     
Pericardiocentesis   /  
Pericardial biopsy   /  
ANA indicates antinuclear antibody; CT, computed tomography; CMR,
cardiac magnetic resonance; ENA, antibodies anti-extractable nuclear antigen;
SSA, Sjogren Syndrome type A;, very high;, high/good;, discrete;
/, low/insufficient; and , not useful. QuantiFERON-TB is an interferon-
release assay used in tuberculosis diagnosis.
Table 8. Management of Pericarditis: Indications for
Pericardiocentesis, Pericardial Biopsy, Pericardioscopy,
Pericardial Window, and Pericardiectomy
Pericardiocentesis
Cardiac tamponade
Moderate to large effusions refractory to medical therapy and with severe
symptoms
Suspected bacterial or neoplastic pericarditis
Advantages: allows drainage and analysis of pericardial fluid
Limits: invasive technique, requires monitoring and hospitalization
Pericardial biopsy and pericardioscopy (targeted biopsy in specialized center)
Relapsing cardiac tamponade
Suspected bacterial or neoplastic pericarditis
Worsening pericarditis (despite medical therapy) without a specific
diagnosis
Advantages: allows analysis of pericardial tissue
Limits: invasive technique, requires monitoring and hospitalization,
possible trigger for pericardial bleeding and recurrences
Pericardial window
Recurrent cardiac tamponade
Recurrent moderate to large effusion refractory to medical therapy and
with severe symptoms
Advantages: allows pericardial drainage or obliteration of pericardial
space preventing or reducing pericardial effusion size
Limits: invasive therapy, requires monitoring and hospitalization, possible
trigger for pericardial bleeding and recurrences
Pericardiectomy
Permanent constrictive pericarditis
Recurrent cardiac tamponade
Advantages: allows partial or almost total removal of diseased pericardial
tissue
Limits: invasive therapy; operatory risk may be not negligible according to
disease stage, comorbidities, and surgeon skill; requires experienced
heart surgery team, monitoring, and hospitalization; possible failure for
incomplete removal; trigger for pericardial bleeding and recurrences
920 Circulation February 23, 2010
D
ow
nloaded from
 http://ahajournals.org by on April 4, 2019
tis, generally with a preserved or mildly reduced left
ventricular ejection fraction (ie, 45% to 50%), has a good
prognosis without evolution to heart failure, constrictive
pericarditis, or increasing recurrence rates.36,37 In these
cases, normalization of the ECG, left ventricular function,
and exercise capacity is reported within 12 months.36
Subtle myocardial involvement beyond ECG changes, eg,
troponin elevation and wall motion abnormalities on echo-
cardiography (usually discordant with ECG changes, un-
like acute coronary syndromes), can also be detected
noninvasively by cardiac magnetic resonance.37 Myoperi-
carditis requires admission for monitoring and therapy. In
myopericarditis, antiinflammatory drugs should be evalu-
ated against the degree of myocardial involvement be-
cause, in animal models of myocarditis, they may enhance
the myocarditic process and increase mortality.36,37 Lower
doses of antiinflammatory drugs (ie, aspirin 500 mg TID)
are usually prescribed mainly to control symptoms for 1 to
2 weeks rather than reaching full high antiinflammatory
effects such as in simple pericarditis.36,37 Exercise restric-
tion is recommended for 4 to 6 weeks, as well as
echocardiographic monitoring of ventricular function (at 1,
6, and 12 months), especially in patients with left ventric-
ular dysfunction in whom angiotensin-converting enzyme
inhibitors and -blockers may be beneficial such as in
heart failure settings.37 For athletes, a return to competitive
sports is considered after 6 months but only if the patient
is asymptomatic with normalization of ECG, markers of
inflammation, left ventricular function, wall motion, and
cardiac dimensions. Moreover, clinically relevant arrhyth-
mias should be absent on Holter monitoring and exercise
test.39,40
Key points: (1) Myocarditis and pericarditis share common
etiologic agents, mainly viruses, with a spectrum ranging
from pure pericarditis to forms with increasing myocardial
involvement (myopericarditis and perimyocarditis); (2) myo-
cardial involvement requires admission for monitoring, and
antiinflammatory therapy is reduced to control symptoms and
Figure 3. A 53-year-old man with apparently idiopathic acute pericarditis: nearly ubiquitous J (ST) elevations with corresponding J (ST)
depression in aVR. As is common in III and aVF when the QRS axis is horizontal (or these leads are of small voltage), the J (ST) is not
elevated. The height of J (ST) is 25% of the height of the T-wave peak in V5 and V6. Most PR segments are slightly depressed with
respect to the T-P baseline (corresponding PR elevation in aVR). In the clinical setting, a spectrum of myopericardial inflammatory syn-
dromes can be encountered, ranging from pure pericarditis to forms with increasing myocardial involvement (sometimes mimicking an
acute coronary syndrome).
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to minimize possible deleterious effects on the myocarditic
process; and (3) prevalent pericarditis (ie, myopericarditis)
generally has a good overall prognosis.
Antiinflammatory Therapy
Corticosteroids
Although reviews and guidelines1,2,17–19 suggest limiting the
use of corticosteroids in inflammatory pericardial syndromes
to patients with intolerance, contraindications, or real failure
of aspirin and other NSAIDs, these drugs are widespread in
general practice, especially for recurrent cases, and the
majority of patients with recurrent pericarditis are treated
with corticosteroids.12,13,20,41,42 The main reason for their
success is that corticosteroids are able to induce a quick
response with symptom control and initial remission. Never-
theless, the treatment often is quickly tapered because of the
fear of possible side effects, and relapses and severe side
effects related to the need of prolonged treatment are com-
mon. Moreover, they are recognized as a risk factor for
recurrences, probably because of impaired virus clear-
ance.19,43–46 Thus, a troublesome issue is how to manage a
patient with recurrent pericarditis and corticosteroid
dependence.
The evidence to support the use of corticosteroids for
pericarditis is rather weak. Specific data come from only 1
retrospective study on recurrent pericarditis.47 In this study,
12 patients with recurrent pericarditis unrelated to any sys-
temic disease were treated for 3 months with high-dose
prednisone (1.0 to 1.5 mg  kg1  d1) for 1 month with
subsequent gradual tapering. When prednisone tapering was
started, all patients received a 5-month course of aspirin (1.6
g/d until steroid withdrawal and then 0.8 g/d). During
follow-up (mean, 42 months), high-dose prednisone resulted
in stable remission in all but 1 patient. Prolonged treatment
with aspirin cannot be excluded to explain the overall good
remission rate. Moreover, 3 patients (25%) had severe
steroid-related adverse effects; 2 were treated with other
immunosuppressive treatments (1 with azathioprine and 1
with cyclophosphamide).
Lower doses of steroids are commonly used to treat
serositis in patients with autoimmune diseases such as sys-
temic lupus erythematosus and Sjo¨gren syndrome.48,49 These
therapeutic schemes might be reasonably applied to recurrent
pericarditis.
A recent retrospective, nonrandomized study challenges
the common practice of using these high doses of corticoste-
roids.50 One hundred patients with recurrent pericarditis were
assigned to 2 alternative therapeutic regimens of prednisone;
one half received “low” doses of prednisone (0.2 to 0.5
mg  kg1  d1), and the other half received prednisone 1.0
mg  kg1  d1. Baseline characteristics were well balanced
across the groups. Each initial dose was maintained for 4
weeks and then slowly tapered. During 5580 patient-months
of follow-up, patients treated with high doses of prednisone
had a higher rate of severe side effects (23.5% versus 2.0%,
respectively; P0.004) but also of recurrences (64.7% versus
32.6%, respectively; P0.003) and disease-related hospital-
izations (31.4% versus 8.2%, respectively; P0.008). On this
basis, a premise for a possible future randomized study, low
doses of corticosteroids may be considered before resorting to
higher doses. Most of the observed severe side effects were
vertebral fractures. Guidelines recommend osteoporosis pre-
vention when corticosteroids are used, an issue often forgot-
ten in practice. Supplementation with calcium and vitamin D
(1500 mg/d and 800 IU/d, respectively) or an activated form
of vitamin D (eg, alfacalcidiol 1 g/d or calcitriol 0.5 g/d)
should be offered to all patients receiving glucocorticoids to
restore normal calcium balance. Moreover, bisphosphonates
are recommended to prevent bone loss in all men and
postmenopausal women in whom long-term treatment with
glucocorticoids is initiated at a dose 5 mg/d of prednisone
or equivalent.51,52 On the contrary, proton pump inhibitors are
not routinely indicated when corticosteroids are used without
NSAIDs.53
A very low tapering only after stable remission with
symptom resolution and normalization of CRP is the key to
successful management of the disease, similar to what is often
done in polymyalgia rheumatica. A critical threshold for
recurrences is a 10- to 15-mg/d dose of prednisone; at this
threshold, very slow decrements as small as 1.0 to 2.5 mg at
intervals of 2 to 6 weeks are useful (Table 9). If symptoms
recur during tapering, every effort should be made not to
increase the dose of or to reinstitute corticosteroids and to
control symptoms by beginning or increasing the doses of
aspirin or NSAIDs.19,48,50 During tapering, colchicine should
always be considered, starting with low doses, eg, 0.5 to 0.6
mg, to improve gastrointestinal tolerability. An alternative
proposed approach to minimize systemic side effects related
to corticosteroids may be the intrapericardial administration
of nonabsorbable corticosteroids,54 but the technique remains
investigational for the most part.44
NSAIDs and Aspirin
Aspirin or NSAIDs remain the mainstay of treatment for
pericarditis (Table 9). Unsatisfactory results are often re-
ported when NSAIDs are used.20,21,55 Some of these failures
are due to low dosages or courses that are too short, with
interruption of the therapy while the disease is still active, as
manifested by persistently elevated CRP. Articles often give
no details on the specific drug. NSAIDs should be used at
appropriate antiinflammatory dosages (eg, aspirin at 2 to 4 g
daily, indomethacin at 75 to 150 mg daily, and ibuprofen at
1600 to 3200 mg daily), considering long courses until
complete normalization of CRP (Table 9). This is particularly
important during corticosteroid tapering.48 The selection of
the specific NSAID should be based on physician experience
and the patient’s previous history (eg, an NSAID that was
effective in previous attacks should be the favorite choice)
and comorbidities; eg, aspirin is the favored choice in patients
with ischemic heart disease or when the patient is already on
aspirin or needs antiplatelet treatment, whereas indomethacin
and other NSAIDs should be avoided in patients with
coronary artery diseases.56–58
The optimal length of treatment is debatable, and CRP
should probably be considered not only for initial diagnosis
but also as a marker of disease activity to guide management
and treatment length. In addition, the need for gradual
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tapering is not well established although often proposed in
recent publications on pericarditis management.10,13,45,46,48
Colchicine
Besides the indication for gout, colchicine is effective for
treating serositis in familial Mediterranean fever.59 Following
this successful use, Rodriguez de la Serna60 first proposed
colchicine for recurrent pericarditis in 1987.
A number of small retrospective studies support the use of
colchicine for recurrent cases (Table 10)43,55,61–63; in addition,
in a retrospective multicenter analysis of 119 patients, corti-
costeroids attenuated the efficacy of colchicine in preventing
recurrent pericarditis.41 On this basis, more for expert con-
sensus than randomized clinical trials, colchicine has been
recommended to treat recurrent pericarditis (class I recom-
mendation) and is considered optional but probably useful in
acute pericarditis (class IIa recommendation) in the 2004
European guidelines.2 The guidelines recommend 2 mg/d for
1 to 2 days, followed by a maintenance dose of 1 mg/d.
The stronger evidence base to support the use of the drug,
above all for primary or secondary prevention of recurrences,
comes from the subsequent first 2 open-label randomized
trials in which colchicine at least halved the recurrence
rate.45,46 In the COlchicine for PEricarditis (COPE) trial,
colchicine (0.5 to 1 mg daily for 3 months) as an adjunct to
conventional treatment significantly decreased the recurrence
rate (actuarial rates at 18 months were 10.7% and 32.3%,
respectively; P0.004; number needed to treat, 5.0) and
symptom persistence at 72 hours (11.7% and 36.7%;
P0.003) in 120 patients with a first episode of acute
pericarditis. In this study, colchicine was discontinued in 5
patients (8.3%) because of diarrhea.45
In the COlchicine for Recurrent Pericarditis (CORE) trial,
colchicine (0.5 to 1 mg daily for 6 months) as an adjunct to
conventional treatment for recurrent pericarditis significantly
decreased the recurrence rate (actuarial rates at 18 months,
24.0% versus 50.6%, respectively; P0.022; number needed
to treat, 4.0) and symptom persistence at 72 hours (9.5%
versus 31.0%, respectively; P0.029) in 84 patients with
recurrent pericarditis.46 In both CORE and COPE, a mainte-
nance dose of 0.5 mg BID was adopted and reduced to 0.5 mg
daily in patients 70 kg; thus, lower doses may be equally
efficacious but with a possible lower rate of side effects.
Treatment was for 3 months in the first episode (COPE) and
6 months in recurrent pericarditis (CORE).45,46 In recurrent
more severe cases, some authors advocate a longer use of the
drug: up to 12 to 24 months after the last recurrence, tailored
to the individual patient and with gradual tapering, consider-
ing that recurrences have been described after colchicine
discontinuation.12,41,48,61 In the United States, colchicine is
usually prescribed as 0.6 mg once or twice a day rather than
0.5 mg once or twice a day.
A sustained antiinflammatory effect may be beneficial in
autoimmune (autoreactive) pericarditis, but whether it may
delay the clearance of an infectious agent is still unclear in
some cases, especially for acute pericarditis. This does not
seem to be the case in the COPE trial, but further evidence is
needed before routine use can be recommended in the first
attack of pericarditis.
Clinicians are often skeptical about the possible utility of
colchicine for pericarditis. Common reasons include further
recurrences on treatment (colchicine halves, but does not
erase all recurrences); failure as monotherapy (efficacy has
been demonstrated almost exclusively for combination ther-
apy with an NSAID or corticosteroid); incorrect use in
chronic pericardial effusions with normal CRP,64,65 a condi-
tion in which colchicine is generally not efficacious; and drug
withdrawal because of gastrointestinal intolerance. Practical
tips to improve drug compliance may be using appropriate
Table 9. Medical Therapy for Pericarditis and Tapering
Regimen of Prednisone in Pericarditis
Drug
Usual Attack
Dose* (Dose
Range)
Time for
Attack
Dose†
Tapering
(Every
1–2 wk)†
Acetylsalicylic
acid
750–1000 mg TID
(2–4 g/d)
First attack:
1–2 wk
750–1000 mg
BID and then
750–1000 mg/dRecurrence:
2–4 wk
Ibuprofen 600 mg TID
(1600–3200 mg)
First attack:
1–2 wk
Recurrence:
2–4 wk
600 mg BID or
400 mg TID and
then 600 mg/d
Indomethacin 50 mg TID
(75–150 mg)
First attack:
1–2 wk
75–150 mg/d
(ie, TID but reduce
the daily dose of 25 mg
every 1–2 wk)
Recurrence:
2–4 wk
Nimesulide 200 mg/d First attack:
1–2 wk
Recurrence:
2–4 wk
100–200 mg/d
Prednisone 0.2–0.5
mg  /kg1  d1
First attack:
2 wk
50 mg: 10 mg/d
every 1–2 wk
Recurrence:
2–4 wk
50–25 mg: 5–10 mg/d
every 1–2 wk
25–15 mg: 2.5 mg/day
every 2–4 wk
15 mg: 1.0–2.5 mg/day
every 2–6 wk
Colchicine 0.5 mg BID
0.5 mg/d
(70 kg)‡
First attack:
3 mo
Recurrence:
6–12 mo
Optional for worse
recurrent cases;
consider tapering
over 2–4 wk
Very slow tapering is recommended especially in recurrent cases. Osteo-
porosis prevention should follow guidelines.2,53 Higher doses of corticosteroids
are not proven to improve the outcome in unselected recurrences but may
increase the risk of side effects, further recurrences, and hospitalization.50–52
*Proton-pump inhibitors are recommended for aspirin and NSAIDs.
†Every decrease in drug dose should be only done if the patient is
asymptomatic and CRP and/or ESR are normal, usually after 1 to 2 weeks or
longer for corticosteroids with prednisone 25 mg/d or equivalent. Minimal
monitoring for antiinflammatory drugs includes blood cell count and CRP at
baseline and weekly until CRP normalizes; for colchicine, consider blood cell
count, CRP, transaminases, creatine kinase, and creatinine at baseline and at
least after 1 month.
‡For colchicine, an attack dose is not necessary (risk of increased rate of
side effects; use the maintenance dose); 0.5 to 0.6 mg/d is the maximum dose
for children 5 years of age and elderly 70 years of age. For renal
impairment, use 0.5 to 0.6 mg/d if creatinine clearance is 35 to 50 mL/min and
0.5 to 0.6 mg/d every 2 to 3 days if creatinine clearance is 10 to 34 mL/min;
it should be avoided if creatinine clearance is 10 mL/min.
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weight-adjusted doses and starting with lower doses without
a loading dose and then increasing the dose if tolerated.
Compared with other drug treatments, colchicine appears to
be one of the cheapest (daily cost of $0.23 in the United
States and €0.13 in Western Europe).
Follow-Up
Uncomplicated cases require relatively few follow-up visits:
at 7 to 10 days to assess response to treatment, at 1 month to
check blood tests and CRP, and thereafter only if symptoms
recur. However, patients with high-risk features or recur-
rences require close monitoring according to symptoms and
laboratory findings (CRP, echocardiography data).
Key points: (1) Corticosteroid therapy is a risk factor for
recurrences and should be restricted to cases with intolerance,
contraindication, or true failure of aspirin or NSAIDs, favor-
ing low to moderate doses (ie, prednisone 0.2 to 0.5
mg  kg1  d1) with very slow tapering; (2) aspirin and
NSAIDs are mainstays of treatment and should be used at full
antiinflammatory doses (eg, aspirin 2 to 4 g daily, indometh-
acin 75 to 150 mg daily, and ibuprofen 1600 to 3200 mg
daily) until symptoms disappear and CRP completely nor-
malizes; and (3) colchicine (usually 0.5 to 0.6 mg BID for
several months or 0.5 to 0.6 mg daily for patients 70 kg) is
useful for halving the recurrence rate when used as adjunct to
other inflammatory drugs.
Management of “Refractory” Cases and
Long-Term Outcome of Idiopathic
Recurrent Pericarditis
Cases that recur after steroid tapering (very common) should
not be considered refractory; this definition should apply to
those cases that require unacceptably high long-term doses of
corticosteroids to be controlled (eg, prednisone 25 mg
daily). They probably represent 5% of recurrent cases. In
this situation, several drugs (azathioprine, cyclophosphamide,
cyclosporine, methotrexate, hydroxychloroquine, intravenous
immunoglobulin, anakinra) have been used21,65,66; azathio-
prine is the preferred choice if tolerated2 (at the common
dosage of 2 to 3 mg  kg1  d1), but it should be acknowl-
edged that strong evidence-based data are lacking. Less toxic
and less expensive drugs (eg, azathioprine or methotrexate)
should be preferred, with the therapy tailored to the individual
patient and physician experience and, importantly, with
informed consent.66 In many cases, combined triple therapy
with a corticosteroid, aspirin or an NSAID, plus colchicine
may be considered in more difficult cases. This approach is
comparable to that adopted in ischemic heart diseases in
which a combination of drugs (ie, nitrates, -blockers,
calcium channel blockers) is prescribed to control symptoms
in more difficult cases.
Long-term outcome of idiopathic recurrent pericarditis has
been considered controversial with a fear of possible evolu-
tion to constrictive pericarditis. Nevertheless, a systematic
review of all publications from 1966 to 2006 including a total
of 230 patients with idiopathic recurrent pericarditis followed
up for 61 months has shown that the overall prognosis is
excellent and complications are uncommon.12 Constrictive
pericarditis was never reported in these patients despite
numerous recurrences, and the overall risk is lower than in
idiopathic acute pericarditis (1%). Thus, it is important to
reassure patients on their prognosis, explaining the nature of
the disease and its likely course. Drug treatment should take
into account this good outcome to avoid more toxic agents.12
Key points: (1) Refractory cases include patients who
require unacceptably high long-term doses of corticosteroids
for control (eg, prednisone 25 mg daily); (2) the first step is
considering the combination of aspirin or an NSAID plus a
corticosteroid and colchicine; (3) other therapies are based on
less solid evidence: (4) less toxic and less expensive drugs
(eg, azathioprine or methotrexate) should be preferred,
with the therapy tailored to the individual patient and
physician experience; and (5) the overall long-term prog-
nosis of idiopathic recurrent cases is very good without
risk of constriction.
Role of Pericardiectomy, Pericardial Window,
and Other Interventional Techniques
The 2004 European Society of Cardiology guidelines2 gave a
class IIa recommendation to pericardiectomy for frequent and
highly symptomatic recurrences resistant to medical treat-
ment. Other reported indications include repeated recurrences
with cardiac tamponade, as well as evidence of serious steroid
toxicity. Although surgical experiences are not always con-
cordant,42,67,68 pericardiectomy is generally considered a ther-
apeutic option of doubtful efficacy in recurrent idiopathic
pericarditis and should be considered only in exceptional
cases (Table 8). We agree with these conclusions; moreover,
the largest retrospective survey with favorable results for
pericardiectomy68 has several limitations. In this retrospec-
tive analysis of the records of 60 patients who underwent
pericardiectomy over a 10-year period (1980 to 1990), both
Table 10. Main Published Studies on the Use of Colchicine to Treat Recurrent Pericarditis
Study Year Design Patients, n
Maintenance
Dose, mg/d
Adjunct to Standard
Therapy Follow-Up, mo Recurrence, n (%)
Guindo et al55 1990 NR 9 1.0 Yes 10–54 0/9 (0.0)
Adler et al62 1994 NR 8 1.0 Yes 18–34 0/8 (0.0)
Millaire et al63 1994 NR 19 1.0 No 32–44 4/19 (21.0)
Adler et al61 1998 NR 51 1.0 Yes 6–128 7/51 (13.7)
Imazio et al43 2005 NR 35 1.0 Yes 48–108 3/35 (8.6)
CORE46 2005 R 84 0.5–1.0 Yes 8–44 9/42 (21.0)
NR indicates nonrandomized; R, randomized.
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patients with and without constriction were included (60%
with constriction, 40% with effusive disease). Only 10% of
patients had pain as the primary symptom necessitating
intervention, and a specific analysis of recurrent symptoms in
patients with effusion and patients with constriction is not
available.
There have been cases in which, for unknown reasons,
pericardial removal has ended the syndrome, but there are
also many cases in which the syndrome either is unchanged
or returns postoperatively after a period of improvement or
even disappearance. In our experience, this frequent “lucent
period” may last from as little as 9 days to 6 months and is
probably responsible for early reports of successful surgery
(ie, the follow-up was inadequate).
At present, indications for pericardiectomy in recurrent
pericarditis are based on expert opinion more than proven
beneficial effects. On the other hand, the benefits of peri-
cardiectomy are well established for permanent constrictive
pericarditis.
All the material is still anecdotal or observational. For
patients with recurrent, particularly incessant, pericarditis
resistant to all medical options, there should be an appropri-
ately designed randomized controlled study, which will
probably be rather difficult to undertake. Nevertheless, such
an investigation might establish the actual frequency of
success with pericardiectomy and may delineate the charac-
teristics of patients who would benefit from it.
Another important and controversial issue is the timing of
pericardiectomy when pericardial constriction is diagnosed.
Transient constriction has been reported in 9% of cases with
effusive acute idiopathic pericarditis in which features of
constriction were recorded in the subacute phase of pericar-
ditis resolution when pericardial effusion had disappeared or
was minimal.69
A subsequent review by the Mayo Clinic of 212 patients
with echocardiographic findings of constrictive pericarditis
recorded 36 patients (17%) with follow-up studies showing
resolution after medical therapy at an interval ranging from 2
months to 2 years. Treatment included NSAIDs, a steroid,
antibiotics, chemotherapy, and angiotensin-converting en-
zyme inhibitors plus diuretics. Five patients had resolution of
constriction without any specific therapy.70
Some patients may go through a transient phase of cardiac
constriction at the end of the effusive period of pericarditis.
Thus, in the absence of evidence that the condition is
permanent and chronic, patients with newly diagnosed con-
strictive pericarditis who are hemodynamically stable may be
given a trial of conservative management (antiinflammatory
therapy with NSAIDs and/or corticosteroids) for 2 to 3
months before pericardiectomy is recommended.70
Less invasive options for recurrent symptomatic effusions
are derived mainly from experience in the management of
neoplastic pericardial effusions and include prolonged cath-
eter drainage and the creation of the so-called “pericardial
window.”71–76 In patients with cardiac tamponade or signifi-
cant effusion, initial relief can easily be obtained with
percutaneous pericardiocentesis followed sometimes by
drainage with an indwelling catheter. Prolonged catheter
drainage is an effective means of preventing fluid reaccumu-
lation, although the mechanism by which this occurs is
probably related more to the obliteration of the pericardial
space after inflammation provoked by the catheter than to
fluid drainage itself. This approach was successful in 70%
of cases, although the duration of effusion control is often not
reported. Catheter drainage may be required for several days,
and the catheter should not be removed until drainage is 20
to 30 mL/24 h.77Alternative strategies include surgical de-
compression of the pericardium (also known as pericardiot-
omy, pericardiostomy, and “window” pericardiectomy) by
either conventional heart surgery or video-assisted thoracos-
copy (Figure 4) with a possible lower incidence of effusion
recurrence compared with pericardiocentesis and prolonged
catheter drainage.72,74
Balloon pericardiotomy is an alternative to surgical cre-
ation of a pericardial window. The technique has been
especially adopted for patients with malignancies and re-
duced life expectancy to improve the quality of life. It
involves inserting a deflated single catheter or double balloon
catheters into the pericardial space using a subxiphoid ap-
proach under fluoroscopic guidance. Although successful in
preventing recurrence in 80% of cases, stretching of the
pericardium is often painful, so appropriate analgesia is
recommended. Reported complications include fever (up to
28%), pneumothorax or need for a chest tube (up to 20%),
and rarely bleeding from a pericardial blood vessel.75,76
Key points: (1) Pericardiectomy is recommended for per-
sistent constrictive pericarditis; (2) patients with newly diag-
nosed constrictive pericarditis who are hemodynamically
stable may be given a trial of conservative management
(antiinflammatory therapy with NSAIDs and/or corticoste-
roids) for 2 to 3 months before pericardiectomy is recom-
mended; and (3) pericardiectomy is almost never indicated
for recurrent pericarditis except for patients with repeated
recurrences with cardiac tamponade and those with evi-
dence of serious steroid toxicity, although other ap-
proaches may be equally effective and less invasive (eg,
pericardial window by either conventional heart surgery or
video-assisted thoracoscopy).
Management of Chronic Idiopathic
Pericardial Effusion
A chronic idiopathic pericardial effusion can be defined as a
collection of pericardial fluid that persists for 3 months and
has no apparent cause; large effusions have a theoretical risk
of progression to cardiac tamponade (up to one third).78 Thus,
some authors have advocated the need for pericardiectomy
for such cases whenever a large effusion recurs after pericar-
diocentesis. Because drainage is relatively safe and easy in
some cases with guided pericardiocentesis, some authors
have advocated drainage for large effusions that are stable
after several weeks (eg, 6 to 8 weeks), especially when there
are signs of right-sided collapse to prevent the possible
decompensation of the effusion after additional events (eg,
pericarditis, bleeding after chest trauma).18 Careful monitor-
ing may be sufficient in many cases, but the course may be
unpredictable with either partial regression of the effusion or
evolution to cardiac tamponade. Unfortunately, there are no
proven effective medical therapies to reduce an isolated
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effusion; in the absence of inflammation, NSAIDs, colchi-
cine, and corticosteroids are generally not efficacious.64,65
Pericardiocentesis alone may frequently resolve large effu-
sions, but recurrences are also common,78 and pericardiec-
tomy or less invasive options (ie, pericardial window) should
be considered whenever fluid reaccumulates, the effusion is
loculated, or biopsy material is required. The need for
intervention in all cases remains controversial and requires
the understanding of the possible benefits but also risks (ie,
possible trigger of recurrences and a new iatrogenic pericar-
dial disease),17,79as well as informed consent. A simplified
approach for pericardial effusion management is reported in
Figure 2.
Key points: (1) Management is guided by the size and
hemodynamic importance of the effusion, the presence of
inflammation (ie, pericarditis), and associated medical con-
ditions; (2) an inflammatory effusion is managed like peri-
carditis, whereas a moderate to severe effusion without
inflammatory signs requires the exclusion of a malignancy or
other medical condition as a possible cause to treat; and (3) a
true isolated effusion may not require a specific treatment if
the patient is asymptomatic, but large ones have a theoretical
risk of progression to cardiac tamponade (up to one third).
Future Perspectives
Further research is needed to evaluate the etiology of recur-
rent pericarditis, especially its relationship with autoimmune
or autoinflammatory diseases, and a possible therapeutical
role of interleukin-1 antagonists.21 Additional investigations
should evaluate the impact and clinical application of peri-
cardioscopy to improve standard diagnostic capabilities and
to develop tailored treatments. Ongoing and future random-
ized clinical trials, registries, and updated guidelines (ie, first
American Heart Association/American College of Cardiol-
ogy guidelines and new European guidelines) are needed to
improve the clinical management of pericardial diseases.
Figure 4. A case of recurrent pleuropericardial effusion after postpericardiotomy syndrome. A, Enlarged cardiac silhouette on chest
x-ray caused by pleuropericardial effusion. B, Large pericardial effusion on echocardiography. C, Sinus tachycardia, low voltage, and
electric alternans are evident on the ECG strip. D, View of the inflamed parietal pericardium on video-assisted thoracoscopy after peri-
cardiocentesis. E, Nonspecific findings of chronic inflammation and fibrosis on histology.
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Conclusions
Limited evidence-based data are available to guide the
management of pericardial diseases. Diagnostic efforts are
worthy if they affect subsequent treatments and prognosis,
and a targeted etiologic search should be directed to the
commonest causes on the basis of clinical background,
epidemiological issues, or specific presentations. Treatment
should be targeted to the cause when available, favoring
aspirin or NSAIDs for idiopathic and viral forms. Corticoste-
roid use should be restricted, and therapeutic schemes starting
with lower doses may be equally or more effective than high
doses, reducing side effects. Colchicine may be a useful drug
to prevent recurrences in inflammatory pericardial syn-
dromes. Pericardiocentesis is indicated for cardiac tampon-
ade; high suspicion of tuberculous, purulent, or neoplastic
pericarditis; and large or symptomatic effusions refractory to
medical treatment. Pericardiectomy should be considered
mainly for persistent chronic constrictive pericarditis.
Disclosures
None.
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